Synthetic, non-intoxicating CBD analogue treats seizures in rats
May 31, 2019Medical Communications CBD, H2CBD, cannabidiol, medicinal cannabis, pharma
A synthetic, non-intoxicating cannabidiol (CBD)-analogue is effective at treating seizures in rats, according to researchers at the University of California, …
Investigational Novartis therapy smashes primary and secondary endpoints in uncontrolled asthma
May 30, 2019Research and Development Novartis, QVM149, asthma, pharma
Novartis has announced the first findings on the efficacy of its investigational asthma therapy QVM149 in the treatment of inadequately …
Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer
May 30, 2019Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Gilead, cco, commercial, pharma
Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer. In her new …
Novo Holdings invests £53.5 million into Oxford Biomedica
May 30, 2019Business Services, Sales and Marketing Novo Holdings, Novo Nordisk, Oxford BioMedica, Shares, cell and gene therapy, lentivirus
Novo Holdings has agreed to buy 10.1% of shares in British firm Oxford Biomedica for £53.5 million. Novo will buy …
Janssen presents strong Phase 3 showing for Darzalex in multiple myeloma subgroup
May 30, 2019Research and Development Janssen, darzalex, pharma
Janssen has lifted the curtain on new Phase 3 data for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (Rd), …
Oklahoma prosecutors say J&J used ‘brainwashing campaign’ to boost opioid sales
May 30, 2019Research and Development J&J, JJ, opioid crisis, opioids, pharma, public health
Oklahoma state prosecutors have accused Johnson & Johnson of engaging in a “cynical, deceitful, multibillion-dollar brainwashing campaign” to boost sales …
Pharma firms paid Italian doctor to promote opioid drugs
May 29, 2019Research and Development Italy, Mundipharma, Purdue, opioids, pharma
Opioid drugmakers paid an Italian pain doctor to promote opioid painkillers as a treatment for chronic pain, Italian prosecutors say. …
FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma
May 29, 2019Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma
Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …
UK government refuses to sign up to WHO pricing transparency resolution
May 29, 2019Research and Development WHA, WHO, access, health UK, pharma, pricing
The UK government has refused to sign up to a global resolution on transparency in drug pricing which urges governments …
FDA approves Theranica’s smartphone-controlled electroceutical device for migraine
May 29, 2019Research and Development FDA, Nerivio Migra, Theranica, migraine, pharma
Biomedical tech company Theranica has secured FDA approval for Nerivio Migra, its wearable, smartphone-controlled electroceutical device, for the acute treatment …
Manchester emerges as genomics research hub
May 29, 2019Research and Development Diagnostics, Manchester, UK, genomics, pharma
Manchester, UK is emerging as a major hub for genomics research, according to a new firm set up in collaboration …
Living with Scimitar syndrome
May 28, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Scimitar syndrome, patient experience, pharma
Katy Baker has lived her entire life with the rare congenital heart defect Scimitar syndrome. She reflects on the system …
Pfizer’s Lyrica fails at Phase 3 in treating primary generalised tonic-clonic (PGTC) seizures
May 28, 2019Manufacturing and Production, Research and Development, Sales and Marketing Lyrica, Pfizer, epilepsy, pharma, trial failure
Pfizer has unveiled new Phase 3 data on the effectiveness of Lyrica (pregabalin) in the adjunctive treatment of primary generalised …
FDA delays Newron Pharmaceuticals’ trial into schizophrenia drug evenamide
May 28, 2019Manufacturing and Production Newron Pharma, evenamide, pharma, schizophrenia
Newron Pharmaceuticals has halted a clinical trial of its schizophrenia drug evenamide after the FDA raised concerns about reports of …
Pharma sector is a bigger polluter than the automotive industry
May 28, 2019Manufacturing and Production CO2, Green, eco-firendly, emissions, pharma, pollution
The pharmaceutical industry is a bigger polluter than the automotive sector, according to a study from researchers at McMaster University. …
FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer
May 28, 2019Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma
Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …
Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy
May 28, 2019Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma
The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …
FDA approves new tests for chlamydia and gonorrhoea
May 24, 2019Medical Communications STIs, chlamydia, gonorrhoea, public health FDA
The FDA has approved two new tests which make it easier to diagnose common STIs. The approval comes after a …
Top Ten most popular articles on Pharmafile.com this week
May 24, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Gilead, J&J, JJ, MSD, Sandoz, pharma, top ten
On the day that UK Prime Minister Theresa May announces her resignation, we look back on the week’s biggest stories …
China approves GSK’s shingles vaccine Shingrix
May 24, 2019Medical Communications, Sales and Marketing China, GSK, Shingrix, pharma, shingles
GSK’s shingles vaccine has secured approval in China, the company said, after the National Medical Products Administration (NMPA) authorised the …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
